✦ LIBER ✦

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia

✍ Scribed by Derek Weycker; Richard L. Barron

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 63 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25239

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of hospitalization risk and a

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia

✍ Mark L. Heaney; Edmond L. Toy; Francis Vekeman; François Laliberté; Bree L. Dori 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

Reply to Comparison of hospitalization r

Reply to Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia

✍ Mark L. Heaney; Edmond L. Toy; Francis Vekeman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Risk and timing of hospitalization for f

Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma

✍ Gary H. Lyman; David J. Delgado 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 1 views

## Background: Hospitalization for chemotherapy-induced febrile neutropenia is associated with substantial cost and may negatively impact clinical outcome due to associated dose attenuation. ## Methods: Medical records of 1355 patients with intermediate-grade non-hodgkin lymphoma receiving cyclop